Lead Product(s): OP-1250,Palbociclib
Therapeutic Area: Oncology Product Name: OP-1250
Highest Development Status: Undisclosed Product Type: Small molecule
Partner/Sponsor/Collaborator: Olema Oncology
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement November 13, 2020
Olema Oncology will evaluate OP-1250, in combination with Pfizer's IBRANCE® in patients with recurrent, locally advanced or metastatic estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative breast cancer. Pfizer will supply IBRANCE for the study.